AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for ...
Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...